Trial Profile
A double-blind, cross-over study of Lisdexamfetamine dimesylate for the treatment of Attention Deficit Hyperactivity Disorder with anxiety disorder and depression comorbidity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 06 Nov 2018 New trial record
- 09 Oct 2018 Results assessing the efficacy of Lisdexamfetamine in adult patients with ADHD with anxiety disorder and depression comorbidity, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.